Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is running a late-stage study on n...

Regeneron Targets Cat Allergy Eye Relief With New Phase 3 Antibody Trial

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. The phase 1/2 study titled “REGN15505 Alone or in Combinatio...

Regeneron Targets Next‑Gen Cancer Immunotherapy With New Phase 1/2 Trial

In a report released today, Eliana Merle from Barclays maintained a Buy rating on Regeneron, with a price target of $917.00. According to TipRanks,...

Barclays Keeps Their Buy Rating on Regeneron (REGN)

Truist Financial analyst Gregory Renza maintained a Buy rating on Regeneron today and set a price target of $772.00. Renza covers the Healthcare se...

Truist Financial Remains a Buy on Regeneron (REGN)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is running a new Phase 4 study in ...

Regeneron Targets Safer Outpatient Myeloma Care With New Linvoseltamab Study

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is facing a federal securities lawsuit alleging that investors were not fully informed about risks t...

Regeneron Pharmaceuticals Lawsuit Alleges Investors Were Misled Before REGN Stock Drops 

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regeneron (REGN), Celldex (CLDX) and Nurix Therapeut...

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Celldex (CLDX) and Nurix Therapeutics (NRIX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Valneva (VALN), Regeneron (REGN) and Telix Pharmaceu...

Analysts Are Bullish on These Healthcare Stocks: Valneva (VALN), Regeneron (REGN)

Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals has finished a mid stage study tes...

Regeneron’s POTS Study Wraps Up: What REGN7544 Could Mean for REGN Investors

Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their ongoing clinical study. The study, officially titled “PRospEctiVe c...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	REGN	$803.48	-0.31%	425.57K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	REGN	$803.48	-0.3%	425.57K
3
4
5
6

REGN

Get Regeneron Pharmaceuticals, Inc. Data in Excel

Get Regeneron Pharmaceuticals, Inc. Data in Excel